Navigation Links
Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
Date:9/24/2008

and continuous development path into Phase II studies during 2009.

ANA598 Data to be Presented at AASLD Meeting

Anadys will present data on ANA598 during three poster sessions at the 59th Annual Meeting of the AASLD, to be held in San Francisco, California, October 31 - November 4, 2008. The full abstracts, which are summarized below, can be viewed at the AASLD website at http://www.aasld.org.

Anadys will present a late-breaker poster at a session beginning at 8:00 a.m. PST on Monday, November 3. The poster, titled "Results of a Phase I Safety, Tolerability and Pharmacokinetic Study of ANA598, a Non-Nucleoside NS5B Polymerase Inhibitor, in Healthy Volunteers", will present data from the first clinical study of ANA598.

Two additional posters will be presented on Tuesday, November 4, 2008:

-- In a poster titled "Antiviral Efficacy of the HCV RNA Polymerase Inhibitor ANA598 in the Chimpanzee Model of HCV Infection", Anadys will present data showing that ANA598 exhibits a substantial antiviral effect against both genotype 1a and 1b virus in HCV-infected chimpanzees. ANA598 was given as single and multiple oral doses and was well-tolerated in the study.

-- In a poster titled "In Vitro Studies Demonstrate that Combinations of Antiviral Agents that Include HCV Polymerase Inhibitor ANA598 have the Potential to Overcome Viral Resistance", Anadys will present the results of in vitro studies that show ANA598 to be strongly synergistic with interferon-alpha. These studies also show that ANA598 retains activity against mutants known to confer resistance to other classes of direct antivirals, including protease inhibitors, nucleoside inhibitors and non-nucleosides that bind at the thumb site. In addition, genotypic mutations resistant to ANA598 will be presented and shown to be fully susceptible to interferon-alpha, a representative protease inhibitor and a representative nucleoside polyme
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV
2. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
3. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
4. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
5. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
6. Oramed Pharmaceuticals Commences Phase 2A Trials of its Oral Insulin Capsule on Type 1 Diabetics
7. Vion Pharmaceuticals Enters into Agreement to Conduct a Phase I/II Clinical Trial of Cloretazine(R) in Combination with Induction Therapy in Poor Prognosis AML Patients
8. Memory Pharmaceuticals and Roche Expand R3487/MEM 3454 Development Program
9. Oramed Pharmaceuticals Launches GLP1-Analog Program, Based on its Proprietary Drug Delivery Platform
10. Cadence Pharmaceuticals Updates Omigard(TM) Clinical Timeline
11. VIA Pharmaceuticals to Present at American Heart Association Scientific Sessions 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... -- DATATRAK International, Inc. (OTCQX: DATA), a ... eClinical solutions for the clinical trials industry, ... 9.0 eClinical Software. This release advances ... service delivery and introduces two new mechanisms ... DATATRAK Learning Center(TM) and the DATATRAK Learning ...
(Date:12/16/2009)... AVAX Technologies, Inc. (Pink Sheets: AVXT) ("AVAX" or ... a bridge loan financing (the "2009 Financing") pursuant ... (the "Agreement") with Firebird Global Master Fund, Ltd., ... a convertible promissory note, due June 30, 2010, ... issued a warrant to purchase an aggregate of ...
(Date:12/16/2009)... RealMed has been ranked the ... 2009 Top 20 Best in KLAS ... RealMed is a dynamic revenue cycle management ... between healthcare providers and all ... specializing in vendor performance measurement in the ...
Breaking Medicine Technology:DATATRAK's eClinical(TM) 9.0 Software Release furthers Vision of DATATRAK ONE(TM) 2DATATRAK's eClinical(TM) 9.0 Software Release furthers Vision of DATATRAK ONE(TM) 3DATATRAK's eClinical(TM) 9.0 Software Release furthers Vision of DATATRAK ONE(TM) 4AVAX Technologies, Inc. Closes Bridge Financing 2AVAX Technologies, Inc. Closes Bridge Financing 3AVAX Technologies, Inc. Closes Bridge Financing 4RealMed Ranked as 2009 'Best in KLAS' Claims and Clearinghouse Service 2RealMed Ranked as 2009 'Best in KLAS' Claims and Clearinghouse Service 3Is hepatic differentiation of embryonic stem cells induced by valproic acid and cytokines 3F 61615 1No muss no fuss miniaturized analysis for complex samples developed 10786 1No muss no fuss miniaturized analysis for complex samples developed 10786 2No muss no fuss miniaturized analysis for complex samples developed 10786 3Extinct moa rewrites New Zealands history 10782 1Extinct moa rewrites New Zealands history 10782 2
... high eradication rates for the most common, ... REINACH, Switzerland, Oct. 26 Arpida ... two pivotal Phase III,clinical trials at the ... (ICAAC)/Infectious Diseases Society of America (IDSA) 46th,annual ...
... at ICAAC -, BRIDGEWATER, N.J., Oct. 26 ... 3, randomized, open-label, ongoing clinical,trial showed that 79 ... mg (two 400 mg tablets) with 100 mg ... (<50 copies/mL) at week 96,compared with 71 percent ...
Other Medicine Technology:Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 2Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 3Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 4Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 5Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 6Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 7Long-Term Study Evaluates Boosted PREZISTA(R) Vs. Lopinavir/Ritonavir as Part of HIV Combination Therapy in Treatment-Naive Adults 2Long-Term Study Evaluates Boosted PREZISTA(R) Vs. Lopinavir/Ritonavir as Part of HIV Combination Therapy in Treatment-Naive Adults 3Long-Term Study Evaluates Boosted PREZISTA(R) Vs. Lopinavir/Ritonavir as Part of HIV Combination Therapy in Treatment-Naive Adults 4Long-Term Study Evaluates Boosted PREZISTA(R) Vs. Lopinavir/Ritonavir as Part of HIV Combination Therapy in Treatment-Naive Adults 5Long-Term Study Evaluates Boosted PREZISTA(R) Vs. Lopinavir/Ritonavir as Part of HIV Combination Therapy in Treatment-Naive Adults 6Long-Term Study Evaluates Boosted PREZISTA(R) Vs. Lopinavir/Ritonavir as Part of HIV Combination Therapy in Treatment-Naive Adults 7Long-Term Study Evaluates Boosted PREZISTA(R) Vs. Lopinavir/Ritonavir as Part of HIV Combination Therapy in Treatment-Naive Adults 8
(Date:12/17/2009)... marketing techniques, life coaching company puts free i-phone & ... http://itunes.apple.com/us/app/attainment-life-management/id345691804?mt=8 . For the Free download. , ... ... -- Utah based Attainment Life Management & Coaching is ... everything in life simplified into one little hand held ...
(Date:12/16/2009)... 16 Austin,s Custom Tops , a ... with Ryan Gray and Hill Country Home Health, a ... Wednesday, December 9th. Fifty people showed up to cheer ... through platefuls of sliders in support of the local ... as a casual bet over who could eat the ...
(Date:12/16/2009)... December 16, 2009 -- Every year in the ... and 57,000 patients die of the disease, making it ... adults, after lung cancer. , As researchers and clinicians ... -- simultaneously generating thousands of studies producing more and ... researcher of cancer and genetics at Case Western Reserve ...
(Date:12/16/2009)... MDRX ) announced today that it will ... six months ended November 30, 2009 before the ... Allscripts management will host a conference call and ... information at 8:30 AM Eastern Standard Time that ... ,, Allscripts fiscal second quarter earnings will be ...
(Date:12/16/2009)... Institute will sponsor a new learning collaborative ... who serve individuals at risk of, or ... plan, medical home and other provider settings. ... webinars on topics, solutions and case studies ... improvement. Each webinar will include a brief ...
Breaking Medicine News(10 mins):Health News:Attainment Life Management & Coaching has just Debuted its Free Application for I-Phone and I-Touch Users 2Health News:Austin-Based Business Co-Sponsors Gastric Feat for Charity 2Health News:New England Journal of Medicine publishes CWRU review of the 'molecular basis of colorectal cancer' 2Health News:New England Journal of Medicine publishes CWRU review of the 'molecular basis of colorectal cancer' 3Health News:Allscripts to Announce Second Quarter Fiscal 2010 Results 2Health News:Allscripts to Announce Second Quarter Fiscal 2010 Results 3Health News:Allscripts to Announce Second Quarter Fiscal 2010 Results 4Health News:New Learning Collaborative to Prepare Clinicians for Better Chronic Care 2Health News:New Learning Collaborative to Prepare Clinicians for Better Chronic Care 3
... - Exhibits Growth In All Existing Markets -, ... Bulletin Board: PMQC, PMQCU, PMQCW), the third largest long-term ... served. The,Company experienced growth across all four of its ... in the New York City,metropolitan area, as well as ...
... HCA Inc. announced,today that it had commenced a ... aggregate principal amount of its outstanding debt. The series,of ... offer (the "Notes"),are listed in the table below with ... conditions of the tender offer are described in an,Offer ...
... novel drug designed to lessen muscle damage from a heart ... Research Institute. Results of the study, available online and to ... Circulation, reflect the first time the drug has been tested ... the activity of an enzyme called delta protein kinase C ...
... CHAPEL HILL, N.C., Feb. 7 Selecting and ... a new,challenge for marketing leaders at pharmas and ... share similar,structure, composition, and responsibilities -- all detailed ... Best Practices, LLC., According to research findings, ...
... on Exercise (ACE) Research Proves Dance Dance ... Revolution (DDR) Can Be a Tremendous Workout, SAN DIEGO, ... that eliminate conventional hand controllers in favor of more,full-body interaction, ... to the test., The ACE commissioned research out of ...
... Brings Leading Clean Indoor Air and Health Advocates Together ... Indoor Air Quality, SOUTHBOROUGH, Mass., Feb. 7 Most ... did you know the Environmental,Protection Agency says levels of indoor ... occasionally even 100 times higher -- than outdoor air,pollution levels? ...
Other Medicine News:Health News:Chem Rx Surpasses 65,000 Residents Served 2Health News:HCA Announces Cash Debt Tender Offer 2Health News:HCA Announces Cash Debt Tender Offer 3Health News:HCA Announces Cash Debt Tender Offer 4Health News:HCA Announces Cash Debt Tender Offer 5Health News:HCA Announces Cash Debt Tender Offer 6Health News:Novel compound may lessen heart attack damage 2Health News:Pharmaceutical Product Commercialization & Governance Best Practices: Securing Talent for Highly-Effective Brand Teams 2Health News:Can a Video Game Make Your Kids More Fit? 2Health News:February is Designated as 'National Care About Your Indoor Air' Month 2Health News:February is Designated as 'National Care About Your Indoor Air' Month 3Health News:February is Designated as 'National Care About Your Indoor Air' Month 4
For the quantitative determination of direct & total bilirubin in serum. Modified Malloy-Evelyn Diazotization Method. Endpoint Reaction Product measured at 540 nm. Linearity: 20 mg/dl...
... first microplate spectrophotometer designed specifically to run ... week. With rugged hardware, proven optical performance ... barrier of traditional spectrophotometry to obtain results ... easily read up to eight, 1 cm ...
... The 1100RS Spectrophotometers ... economical. Great for use ... laboratories, including educational, clinical, ... Options include COD vial ...
Spectra 3000RS & Spectra 3000RSP are very precise instruments. They have a metal base structure, durable parts for long life use, and they are very easy to use and maintain....
Medicine Products: